Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
Cells. 2020 Dec 4;9(12):2600. doi: 10.3390/cells9122600.
Tumors remodel their metabolism to support anabolic processes needed for replication, as well as to survive nutrient scarcity and oxidative stress imposed by their changing environment. In most healthy tissues, the shift from anabolism to catabolism results in decreased glycolysis and elevated fatty acid oxidation (FAO). This change in the nutrient selected for oxidation is regulated by the glucose-fatty acid cycle, also known as the Randle cycle. Briefly, this cycle consists of a decrease in glycolysis caused by increased mitochondrial FAO in muscle as a result of elevated extracellular fatty acid availability. Closing the cycle, increased glycolysis in response to elevated extracellular glucose availability causes a decrease in mitochondrial FAO. This competition between glycolysis and FAO and its relationship with anabolism and catabolism is conserved in some cancers. Accordingly, decreasing glycolysis to lactate, even by diverting pyruvate to mitochondria, can stop proliferation. Moreover, colorectal cancer cells can effectively shift to FAO to survive both glucose restriction and increases in oxidative stress at the expense of decreasing anabolism. However, a subset of B-cell lymphomas and other cancers require a concurrent increase in mitochondrial FAO and glycolysis to support anabolism and proliferation, thus escaping the competing nature of the Randle cycle. How mitochondria are remodeled in these FAO-dependent lymphomas to preferably oxidize fat, while concurrently sustaining high glycolysis and increasing de novo fatty acid synthesis is unclear. Here, we review studies focusing on the role of mitochondrial FAO and mitochondrial-driven lipid synthesis in cancer proliferation and survival, specifically in colorectal cancer and lymphomas. We conclude that a specific metabolic liability of these FAO-dependent cancers could be a unique remodeling of mitochondrial function that licenses elevated FAO concurrent to high glycolysis and fatty acid synthesis. In addition, blocking this mitochondrial remodeling could selectively stop growth of tumors that shifted to mitochondrial FAO to survive oxidative stress and nutrient scarcity.
肿瘤重塑其代谢以支持复制所需的合成代谢过程,以及在其不断变化的环境中生存下来所必需的营养物质匮乏和氧化应激。在大多数健康组织中,从合成代谢到分解代谢的转变导致糖酵解减少和脂肪酸氧化 (FAO) 增加。这种用于氧化的营养物质选择的变化受葡萄糖-脂肪酸循环(也称为兰德尔循环)调节。简而言之,这个循环包括由于细胞外脂肪酸可用性增加导致肌肉中线粒体 FAO 增加而引起的糖酵解减少。关闭循环,细胞外葡萄糖可用性增加引起的糖酵解增加导致线粒体 FAO 减少。糖酵解和 FAO 之间的这种竞争及其与合成代谢和分解代谢的关系在一些癌症中是保守的。因此,即使将丙酮酸分流到线粒体以转化为乳酸,也可以减少糖酵解来阻止增殖。此外,结直肠癌细胞可以有效地转向 FAO 以在葡萄糖限制和氧化应激增加的情况下存活,代价是减少合成代谢。然而,B 细胞淋巴瘤和其他癌症的一部分需要同时增加线粒体 FAO 和糖酵解以支持合成代谢和增殖,从而逃避兰德尔循环的竞争性质。在这些依赖 FAO 的淋巴瘤中,线粒体如何重塑以优先氧化脂肪,同时维持高糖酵解和增加从头脂肪酸合成尚不清楚。在这里,我们回顾了专注于线粒体 FAO 和线粒体驱动的脂质合成在癌症增殖和存活中的作用的研究,特别是在结直肠癌和淋巴瘤中。我们得出的结论是,这些依赖 FAO 的癌症的特定代谢缺陷可能是一种独特的线粒体功能重塑,许可同时升高的 FAO 与高糖酵解和脂肪酸合成。此外,阻断这种线粒体重塑可以选择性地阻止转向线粒体 FAO 以在氧化应激和营养物质匮乏中存活的肿瘤生长。